Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancer
These results support the clinical utility of HER2 assessment on CTCs with both workflows and highlight the potential diagnostic value of label-free CTC enrichment combined with HER2 quantification. Further studies in larger cohorts should be conducted to validate our findings and investigate the clinical relevance of HER2-positive CTCs detected with the developed pipeline, particularly in the context of anti-HER2 therapies.
Authors
- Eleni Andreopoulou
- Eleonora Nicolò (ORCID: https://orcid.org/0000-0001-5042-6550)
- Brenno Pastò (ORCID: https://orcid.org/0009-0001-3738-6715)
- Mara Serena Serafini (ORCID: https://orcid.org/0000-0001-9192-9170)
- Letizia Pontolillo (ORCID: https://orcid.org/0009-0006-3363-8512)
- Jyothi Manohar
- Laura Muñoz-Arcos (ORCID: https://orcid.org/0000-0002-0229-9056)
- Caterina Gianni (ORCID: https://orcid.org/0000-0001-9496-6719)
- Carolina Reduzzi (ORCID: https://orcid.org/0000-0003-0514-0152)
- M. Cristofanilli
- Nadia Bayou
- Olivier Elemento
- Sarah Henretta (ORCID: https://orcid.org/0000-0001-9891-3104)
- Hunter Andrew Gaudio
- Muhammad Maaz Khan Afghan
- Elisabetta Molteni
- Maroua Manai
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Udine (IT)
- Cornell University (US)
- Lander Institute (IL)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Institut Pasteur de Tunis (TN)
- Weill Cornell Medicine (US)
- Tunis El Manar University (TN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1186/s12935-025-04036-x
- Citations
- 1
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 1.05